Merck & Company Inc () has gone from patent-cliff worry to large-cap pharma comeback story.
Not long ago, the stock was being valued like a mature drugmaker with one giant problem: Keytruda. Merck’s blockbuster cancer therapy remains one of the most important drugs in the world, but its eventual loss of exclusivity has long raised concerns about a future revenue gap. For investors, the question was simple: What does Merck look like after Keytruda’s peak years?
That concern has not gone away, but the market is starting to see a broader story. Over the last month, Merck shares have climbed more than 10%, and over the last 52 weeks, the stock is up closer to 60%. For a company that had been weighed down by patent cliff anxiety, that is a meaningful reset in expectations.
The reason is that Merck is doing more than defending Keytruda. The company is expanding the drug into additional indications, advancing a subcutaneous formulation, building out its oncology pipeline, and developing new growth drivers across HIV, pulmonary arterial hypertension, cardiovascular disease, vaccines, and animal health. Recent regulatory and clinical updates have added to the sense that Merck may have more tools to manage the post-Keytruda transition than investors previously gave it credit for.
That improving fundamental picture now lines up with a constructive Sigmanomics backdrop. The model currently shows bullish forecasts across the 7-day, 14-day, and 28-day timeframes, suggesting the recent rally may still have room to run if momentum holds.
The question is whether the fundamentals can support that follow-through. In Merck’s case, the answer is more encouraging than it was a few months ago. The pipeline story has strengthened, the growth outlook has broadened, and the Keytruda risk looks more manageable. If Merck keeps delivering clinical and regulatory progress while continuing to demonstrate the depth of its next growth phase, the re-rating should have more room to run.
What Merck Does—and Why Recent Developments Matter
Merck is one of the world’s largest pharmaceutical companies, with major franchises across oncology, vaccines, infectious disease, cardiovascular medicine, and animal health. But for investors, the Merck story still starts with Keytruda.
Keytruda has been one of the most important cancer drugs in the world, and it remains the centerpiece of Merck’s earnings power. That strength is also the source of the stock’s biggest risk. With Keytruda’s U.S. exclusivity expected to come under pressure later this decade, investors have spent years asking whether Merck can build enough new revenue streams to avoid a sharp falloff.
That concern hasn’t been completely alleviated. But recent developments suggest the company is making real progress. In oncology, Merck recently received a positive European CHMP opinion for Keytruda plus Padcev as a perioperative treatment for certain adults with muscle-invasive bladder cancer, based on Phase 3 data showing benefits across event-free survival, overall survival, and pathologic complete response rate.
Merck also received encouraging lung cancer news tied to sacituzumab tirumotecan, or sac-TMT, an antibody-drug conjugate being developed with Kelun-Biotech. In a late-stage China trial, sac-TMT plus Keytruda reduced the risk of disease progression or death by 65% versus Keytruda alone in certain advanced non-small cell lung cancer patients, with a reported response rate of 70.2% versus 42% for Keytruda alone.
Those updates are critical because they point directly at the central question surrounding Merck: can the company extend its oncology leadership beyond the original Keytruda cycle? The answer is still uncertain, but the evidence is becoming more constructive.
Merck’s broader portfolio is also expanding. IDVYNSO, its once-daily two-drug HIV regimen, recently received FDA approval for adults with virologically suppressed HIV-1 who meet specific treatment-history and resistance criteria. Merck described it as the first non-INSTI, tenofovir-free, once-daily complete two-drug regimen to demonstrate non-inferior efficacy in a head-to-head Phase 3 trial versus Biktarvy.
Winrevair is another important piece of the diversification story. The drug is approved for adults with pulmonary arterial hypertension and is designed to improve exercise capacity and functional class while reducing clinical worsening events, including hospitalization, lung transplantation, and death.
It is also starting to show real commercial traction. Winrevair sales rose from $280 million in Q1 2025 to $525 million in Q1 2026, an 87% increase, driven by continued growth in new patient starts and total prescriptions. That gives Merck another high-value growth driver outside oncology, supporting the case that its post-Keytruda profile may be more diversified than the market once assumed.
Source: Merck Q1 2026 Earnings Presentation
Taken together, these developments do not eliminate the Keytruda patent risk. But they do change the shape of the story. Merck is no longer just asking investors to look beyond a patent cliff. It is giving them more reasons to believe there may be a bridge to the next phase of growth, built around new formulations, combination therapies, pipeline assets, and portfolio diversification.
That is why the recent rally matters. The market appears to be shifting from “Merck has a Keytruda problem” toward “Merck may have a credible post-Keytruda plan.”
Valuation Reflects a Stronger Story, but Also Higher Expectations
After Merck’s strong rally, the valuation case has become more nuanced. MRK no longer looks like a deeply discounted large-cap pharma stock weighed down by Keytruda patent-cliff fears. It now trades more like a company investors believe can manage that transition through a broader pipeline, new formulations, and additional growth drivers beyond its flagship cancer franchise.
That shift is visible in the multiples. MRK trades at roughly 22x trailing GAAP earnings, modestly below an industry average closer to 24x. However, the stock also trades at about 4.4x sales, compared with an industry average near 3.7x, and roughly 6.2x book value, versus an industry average closer to 2.8x.
In other words, the market is already assigning Merck some credit for its improved outlook. Earlier in the cycle, the stock appeared to reflect heavier skepticism around the eventual loss of Keytruda exclusivity. After a strong 52-week rally, that discount has narrowed, and the bar for continued upside is higher.
That does not weaken the investment case, but it does change the nature of it. Merck is no longer simply a value story built around excessive patent-cliff pessimism. The stronger argument is that investors are beginning to view the company less as a one-drug story facing a revenue cliff and more as a diversified pharmaceutical leader with a credible transition plan.
If Keytruda erosion proves sharper than expected, or if newer products fail to scale, today’s valuation could leave the stock vulnerable to a reset. But if subcutaneous Keytruda, expanded oncology indications, Winrevair, IDVYNSO, vaccines, animal health, and antibody-drug conjugate partnerships continue to broaden the growth base, Merck may be able to sustain a premium multiple.
Analyst sentiment remains constructive. Of the 29 analysts covering the stock, 19 rate MRK a buy and 10 rate it a hold. With shares recently trading near $121 and the average price target around $131, Wall Street still sees additional upside, even after the rally.
Source: Barchart
The bottom line is that Merck is no longer trading like a patent-cliff discount story. Investors are giving the company more credit for its pipeline, diversification strategy, and path beyond Keytruda. That makes the valuation more demanding, but still defensible if Merck can keep turning clinical progress and new product growth into durable earnings power.
Sigmanomics Forecasts Support the Bullish Setup
Sigmanomics adds a tactical layer to the Merck story, and the broader message remains constructive. The model’s near-term and longer-term forecasts both lean bullish, suggesting MRK’s recent momentum may still have room to extend as long as the stock continues to hold above key support levels.
The 7-day forecast shows a bullish bias, with an expected zone of roughly $121 to $130. With MRK recently trading near $122, the stock is already inside that zone, which the model classifies as a valid long entry. The target sits near the upper end of the range at about $130, while a close below roughly $117 would invalidate the setup.
That near-term signal fits the current market backdrop. Merck has already rallied sharply, but recent pipeline news, European regulatory support, and renewed interest in the company’s post-Keytruda transition have helped keep momentum intact.
The 14-day forecast is more mixed, with a bearish bias and an expected zone of roughly $118 to $124. That suggests some digestion of the recent move would not be surprising, especially after the stock’s strong 52-week advance. But the weaker risk/reward profile in that window makes it less central to the broader setup.
The 28-day forecast shifts the focus back to the bullish side. It shows a bullish bias, with MRK inside a wider expected zone of roughly $117 to $186. The model’s upside target sits near the upper end of that range, while the longer-term setup would be invalidated by a close below roughly $82.
Sigmanomics
Taken together, the Sigmanomics data supports a constructive read on Merck. The 7-day forecast points to continued near-term momentum, while the 28-day forecast leaves room for a broader bullish extension. The 14-day signal introduces some caution, but it does not undermine the larger setup.
That lines up with the fundamental story. MRK is no longer a cheap patent-cliff recovery trade, but the pipeline narrative is improving at the right time. If new indications, subcutaneous Keytruda, Winrevair, IDVYNSO, and Merck’s broader oncology platform continue to strengthen the post-Keytruda case, the stock may have enough support to extend its re-rating.
The Bottom Line
Merck is no longer being priced like a company defined by one looming patent cliff.
After a powerful 52-week rally, MRK now reflects a more optimistic view of what comes next. Investors are giving management more credit for its ability to navigate the Keytruda transition, broaden the revenue base, and keep growth intact beyond its flagship cancer franchise. That makes the setup more demanding, but also more compelling.
So far, Merck is giving the market reasons to stay engaged. Keytruda remains the anchor, but the story around it is shifting. New indications, combination therapies, subcutaneous Keytruda, Winrevair, IDVYNSO, vaccines, and oncology pipeline assets all point to a company building a more credible bridge beyond its flagship cancer franchise.
That is the central question from here: can pipeline momentum translate into durable commercial growth? If the answer is yes, today’s premium may prove more reasonable than it looks on headline multiples. If the answer is no, the recent re-rating could be vulnerable to a reset.
For now, however, the balance of evidence leans constructive. MRK has strong price momentum, analysts remain broadly bullish, recent news flow has strengthened the post-Keytruda narrative, and Sigmanomics forecasts support a bullish near-term and longer-term setup.
